IRCT20221218056854N1 IRCT 2023-01-23 Ilam University of Medical Sciences Comparison of the mean effect of Remifentanil, Methadone, and Sufentanil on Pain and Delirium in Patients with spinal surgery Comparison of the mean effect of Remifentanil, Methadone, and Sufentanil on Pain and Delirium in Patients with spinal surgery 2023-01-21 anticipated 120 Complete https://irct.ir/trial/67506 interventional Randomization: Not randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Blinding description: The Patients with Spinal Surgery whom are entering the study are divided to three groups and receive Remifentanil, Sufentanil and Methadone randomly and they aren't aware of which kind of drugs they receive and the other Patients Information(are blinded). 3 multiple fractures of spine, level unspecified. Intervention 1: Intervention group: patients with spinal surgery whom received Remifentanil Infusion as Remifentanil Hydrochloride I.V. 1mg, sold under the brand name EPAXIR, Exir Pharmaceutical Co. with Dosage: 0.05 to 2 μg/kg Injected at the surgery time and 30 minutes after anesthesia. Intervention 2: Intervention group: patients with spinal surgery whom received Sufentanil Infusion as Sufentanil Citrate I.V. 50μg sold under the brand name SUFIJECT, Aburaihan Pharmaceutical Co. with Dosage: 2.5 to 15 μg/kg Injected at the surgery time and 30 minutes after anesthesia. Intervention 3: Intervention group: patients with spinal surgery whom received Methadone Infusion as Methadone Hydrochloride I.V. 5mg/ml sold under the brand name Methadone, Darou Pakhsh Pharmaceutical Co. with Dosage: 20mg Injected at the surgery time and 30 minutes after anesthesia. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No Further Information Available